激光或抗VEGF单药治疗后早产儿视网膜病变复发率及危险因素
该回顾性队列研究纳入176例(340眼)1型早产儿视网膜病变患儿,分别接受激光、玻璃体腔贝伐珠单抗(IVB)或雷珠单抗(IVR)单药治疗。总体复发率为12.9%,三组间无显著差异;抗VEGF组复发时间更晚,独立危险因素包括初次治疗时矫正胎龄早、I区病变、低Apgar评分和多胎。
要点
- 1型ROP治疗后总体复发率为12.9%(44/340眼),三组间无显著差异(P=0.0528)。
- 抗VEGF组复发时间晚于激光组,需延长随访至矫正胎龄50周左右。
- 独立危险因素包括初次治疗时矫正胎龄早、I区病变、低Apgar评分和多胎。
核心结论
- 激光、IVB和IVR单药治疗1型ROP均有效,但抗VEGF治疗后复发时间更晚,需延长随访。
研究设计与样本
- 回顾性队列研究,纳入176例(340眼)1型ROP患儿,随访至少至矫正胎龄75周,数据分析于2010年3月至2017年2月在台湾长庚纪念医院林口院区进行。
主要发现
- 总体复发率为12.9%(44/340眼),IVB组10.0%、激光组18.0%、IVR组20.8%,三组间无显著差异(P=0.0528)。
- 复发时矫正胎龄:IVB组43.4±3.5周、IVR组42.3±2.0周、激光组39.5±2.8周(P=0.0058)。
- 复发距初次治疗间隔:激光组3.6±1.4周、IVB组8.8±3.9周、IVR组8.3±1.6周(P=0.0001)。
- 进展为视网膜脱离的比例三组间无显著差异(激光组4.9%、IVB组0.9%、IVR组2.1%,P=0.2701)。
关键数值与推荐
- 独立复发危险因素:初次治疗时矫正胎龄早(P=0.0160)、I区病变(P=0.0007)、低Apgar评分(P=0.0297)、多胎(P=0.0285)。
临床怎么用
- 抗VEGF单药治疗后复发可晚至矫正胎龄50周,应延长随访直至该阶段。
- 对初次治疗时矫正胎龄早、I区ROP、低Apgar评分或多胎患儿应加强随访。
局限性
- 回顾性研究设计,单中心数据,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the rates and risk factors of recurrent retinopathy of prematurity (ROP) treated by laser photocoagulation, intravitreal bevacizumab (IVB) monotherapy, or intravitreal ranibizumab (IVR) monotherapy. METHODS: In this retrospective cohort study, consecutive infants with Type 1 ROP who received laser, IVB, or IVR treatments were followed for at least 75 weeks of postmenstrual age. Data analysis was performed between March 2010 and February 2017 in Chang Gung Memorial Hospital, Linkou, Taiwan. RESULTS: A total of 176 infants (340 eyes) were included in this study. The mean follow-up was 197.3 ± 110 weeks. All of the baseline demographic and ROP characteristics among the laser, IVB, and IVR groups were similar. The overall recurrence rate after treatment was 44 of 340 eyes (12.9%). The IVB group had a recurrence rate of 10.0%, followed by the laser group (18.0%) and the IVR group (20.8%); however, these rates were not significantly different (P = 0.0528). Compared with the laser group, the IVB and IVR groups exhibited recurrence at later ages (43.4 ± 3.5 weeks for the IVB group, 42.3 ± 2.0 weeks for the IVR group, and 39.5 ± 2.8 weeks for the laser group; P = 0.0058). The mean interval of recurrence from initial treatment in the laser group was 3.6 ± 1.4 weeks compared with 8.8 ± 3.9 weeks and 8.3 ± 1.6 weeks in the IVB and IVR groups, respectively (P = 0.0001). Overall, the independent risk factors of recurrence included an early postmenstrual age at initial treatment (P = 0.0160), Zone I (P = 0.0007), low Apgar score (P = 0.0297), and multiple births (P = 0.0285). There was no significant difference in progression to retinal detachment among the three groups (laser: 3/61, 4.9%; IVB: 2/231, 0.9%;and IVR: 1/48, 2.1%; P = 0.2701). CONCLUSION: Laser, IVR, and IVB are effective for Type 1 ROP. Retinopathy of prematurity recurrence requiring re-treatment was encountered as late as 50 weeks of postmenstrual age after IVB or IVR but earlier after laser. Longer follow-up for infants treated with anti-vascular endothelial growth factor is needed, especially in patients with significant risk factors such as an early postmenstrual age at initial treatment, Zone I ROP, low Apgar score, and multiple births.
引用
- Ling KP, Liao PJ, Wang NK, et al. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY. Retina. 2020. PMID: 31800460. doi:10.1097/IAE.0000000000002663
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。